



Alyra Therapeutics

Next-generation precision oncology

Founded in 2020, Alyra Therapeutics is developing proprietary drugs that target proteins of the *ras* oncogene family. These proteins underpin the pathobiology of melanoma and other difficult-to-treat cancers which comprise a \$3+ B TAM in oncology indications alone. Our focus is on two protein targets: (1) the *ras* protein RHOJ, a signal protein involved in tumor angiogenesis and metastasis and (2) its effector protein, p21 activated kinase (PAK1). In addition to its independent angiogenic activity, RHOJ binds to PAK1, activating PAK1 to trigger its involvement in tumor initiation and growth. Both are overexpressed in multiple tumors and certain rare diseases.

Our clinical candidate is ALY101, a RHOJ/PAK1 dual inhibitor which binds to RHOJ, inhibiting both its autonomous activity and its ability to bind to and activate PAK1, suppressing tumor initiation, angiogenesis and metastasis in multiple models of melanoma and other cancers.

Alyra co-founders Drs. Anand Ganesan and Marco De Vivo are based in Irvine, California at the University of California Irvine (UCI), and in Genoa, Italy, at the Italian Institute of Technology (IIT). Dr. Ganesan is Professor in the Departments of Dermatology and Biological Chemistry at the UCI School of Medicine. Dr. De Vivo is Group Leader of the Molecular Modeling & Drug Discovery Lab at IIT. The other co-founders, Drs. Mark Benedyk and Alessandro Monge have significant business development and strategy experience at companies such as Schrödinger, Pfizer, Elan and multiple venture-backed companies. Also on our team is Dr. Jay Stoudemire, our Head of Nonclinical Development. He brings to Alyra a wealth of oncology drug development experience from his tenure at companies such as Chugai, Sumitomo Dainippon Pharma and Genentech/Roche.

The Company has exclusive global rights to compounds jointly developed under the collaboration between the Ganesan and De Vivo laboratories and is headquartered in San Diego, California.

ALY101 demonstrates precise specificity for the RHOJ-PAK1 interaction based on a screen across multiple common drug targets. We have identified a backup to our ALY101 clinical lead and candidate selection from a second chemical series of compounds with similar activity is underway. We are in the process of completing additional formulation and DMPK and TK work, targeting completion of IND-enabling studies in 2021 in order to file the ALY101 IND in late Q4 2021.

We are raising \$0.25 M in convertible debt to conduct additional *in vivo* experiments in preparation for a \$5 M Series A round which will finance IND-enabling studies of ALY101 under our operating plan for filing of the ALY101 IND in Q4 2021.